Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.52 |
| ▸ | TGM2 | P21980 | 2/20 | 0.50 |
| ▸ | BLK | P51451 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | PNLIP | P16233 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968532 | 0.88 | TGM2 (0.65) | BRD4TGM2BLKEGFRITK | |
| SCHEMBL24969112 | 0.88 | FFAR1 (0.53) | BRD4TGM2BLKEGFRITK | |
| SCHEMBL24968527 | 0.86 | TGM2 (0.60) | BRD4TGM2BLKBRAFKDR | |
| SCHEMBL24968520 | 0.85 | FFAR1 (0.55) | BRD4TGM2BLKEGFRITK | |
| SCHEMBL21392902 | 0.84 | TGM2 (0.71) | TGM2BLKEGFRERBB2BTK | |
| SCHEMBL24969114 | 0.81 | TGM2 (0.57) | BRD4TGM2EGFRBRAFKDR | |
| SCHEMBL24969094 | 0.80 | EGFR (0.61) | TGM2EGFRITKERBB2 | |
| SCHEMBL24968831 | 0.80 | TGM2 (0.46) | TGM2EGFRITKERBB2BTK | |
| SCHEMBL30152207 | 0.80 | TGM2 (0.46) | TGM2EGFRITKERBB2BTK | |
| SCHEMBL24968529 | 0.78 | BRAF (0.49) | BRD4TGM2EGFRITKBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |